Anakinra – Page 6 – Communicable Diseases Research

The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response

코로나19 환자에서 SARS-CoV-2에 대한 항체 반응에 대한 토실리주맙, 아나킨라 및 프레드니솔론의 효과: 항체 반응에 영향을 미치는 요인에 대한 다변량 분석을 통한 전향적 코호트 연구

Article

Published on 2021-04-012022-09-12
Journal: International Journal of Infectious Diseases [Category] SARS, 진단,

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

토실리주맙-불응성 중증 COVID-19에 대한 아나킨라의 효과: 단일 센터 후향적 비교 연구

Comparative Study

Published on 2021-04-012022-09-12
Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단,

Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists

소아 코로나19에 대한 치료적 접근: 소아 류마티스 전문의를 대상으로 한 온라인 설문조사

Observational Research

Published on 2021-03-082022-09-10
Journal: Rheumatology International [Category] SARS, 치료제,

[키워드] “cytokine storm” Anakinra anti-CD20 approach Autoimmune disease Azithromycin board Bulletin Board canakinumab children Corticosteroid Corticosteroids COVID-19 Critical Critically ill Critically ill patient critically ill patients Cyclophosphamide Cytokine storm disease Evidence healthy children Hydroxychloroquine Immunoglobulin immunoglobulins immunomodulating Immunosuppressed Inflammation International Intravenous immunoglobulin intravenously knowledge management Mild Opinion poll oxygen oxygen supply patients with COVID-19 pediatric Pediatric rheumatology reduced Remdesivir rheumatologist SARS-CoV-2 Stage stage I stage II stage III supplementary material Support Therapeutic approach therapeutic approaches therapy Tocilizumab Treatment
[DOI] 10.1007/s00296-021-04824-4 PMC 바로가기 [Article Type] Observational Research

An open label trial of anakinra to prevent respiratory failure in COVID-19

COVID-19에서 호흡 부전을 예방하기 위한 아나킨라의 공개 라벨 시험

Clinical Trial

Published on 2021-03-082022-08-13
Journal: eLife [Category] SARS, 바이오마커, 임상,

[키워드] 30-Day mortality 95% CI Administering Anakinra antagonists approach Arthritis assigned balance Biomarker blood protein blood sample Care cause circulating class clinical Combination COVID-19 COVID-19 patients death rate death rates decrease defined develop drug effective examined form framework funding hazard ratio help highest Horizon Human identify immune function immune response immune system IMPROVE incidence individual infected individual Infection Inflammation Inflammatory Inflammatory mediators injection interleukin-10 investigated less marker medication medications non-invasive ventilation once daily open label outcome Pain Patient Pneumonia Prevent Primary outcome progressed progression Protein receptor reduce reduced respiratory Respiratory failure respiratory ratio respond restored rheumatoid arthritis risk risk of death Safe SARS-CoV-2 SARS-CoV-2 virus secondary outcome Sepsis severe respiratory failure Side effects significantly SOFA SOFA score soluble urokinase plasminogen activator receptor SRF suggested suPAR Swedish Orphan Biovitrum swelling the SARS-CoV-2 virus treat treating COVID-19 patient Treatment Trial ventilator while WHO-CPS
[DOI] 10.7554/eLife.66125 PMC 바로가기 [Article Type] Clinical Trial

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Randomized Controlled Trial

Published on 2021-03-012022-10-05
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상,

[키워드] 1:1 95% CI acute respiratory syndrome Admission adverse event age Anakinra analysed Analysis AP-HP ARD assigned Bayesian block size blocked with C-reactive protein Care clinical clinical trial Clinicians Clinique Cohort Concentration coronavirus COVID-19 CrI cytokine determine died Effect Efficacy foundation France group hazard ratio High-flow oxygen hospital IL-1 IL-1 receptor antagonist IMPROVE Infection Inflammation intensive care intention-to-treat basis IQR less mechanical ventilation median men Mild-to-moderate Ministry of Health monitoring board multicentre nasal Non-invasive non-invasive ventilation occurred Open-label outcome oxygen participant Patient patients Pneumonia posterior probability proportion provided randomised randomised controlled trial Randomly real-time RT-PCR recruited recruitment Registered risk scale screened secure selected serum severe COVID-19 stratified survival the median the WHO Trial Two patient university usual care usual care alone usual care group Ventilation WHO-CPS with COVID-19
[DOI] 10.1016/S2213-2600(20)30556-7 PMC 바로가기 [Article Type] Randomized Controlled Trial

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment

신장 및 간 장애 환자의 용도 변경 COVID-19 약물 투여에 대한 권장 사항

Review

Published on 2021-03-012022-09-11
Journal: Drugs in R&D [Category] MERS, 신약개발, 임상, 치료제,

[키워드] acute infection acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Affect Altered Anakinra anticipated Antiviral Atazanavir available data Azithromycin clinician complex coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 in patient Dexamethasone Dosing drug drug concentration drug concentrations drug interaction Efficacy excretion experimental drug Experimental drugs Favipiravir Guidance hepatic hepatic disease hepatic function hepatic impairment Hydroxychloroquine immune indications Injury interferon beta Limited Lopinavir Lopinavir/ritonavir medication medications metabolism outbreak Patient patients with COVID-19 pharmacokinetic pharmacokinetics produced recommendation reduced regimen Remdesivir renal renal or hepatic impairment respiratory resulting ribavirin Ritonavir sarilumab SARS-CoV-2 significantly therapy Tocilizumab toxicities Toxicity treat Treatment treatment for COVID-19 Trial University of Liverpool Variability was performed website
[DOI] 10.1007/s40268-020-00333-0 PMC 바로가기 [Article Type] Review

Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic

Pediatrics

Published on 2021-02-232022-10-31
Journal: Frontiers in Pediatrics [Category] COVID-19,

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist

코로나19 시대 중증 과염증 관리: 류마티스내과의 역할

Clinical Science

Published on 2021-02-162022-09-01
Journal: Rheumatology (Oxford, England) [Category] MERS, 진단, 치료제,

[키워드] abdominal pain aciclovir Anakinra Antiviral approach Asian black case note children clinical framework clinical trials Complete contribute COVID-19 Definition diagnostic Diagnostic Criteria differential diagnose differential diagnoses focus Follow-up framework highlight hyperinflammation Immunoglobulin immunomodulation immunomodulatory therapy Inflammatory infliximab involved Kawasaki disease Laboratory parameters median age multidisciplinary team objective outcome overlapping paediatric inflammatory multisystem syndrome Patient referred to Result retrospective rheumatologist SARS-CoV-2 Shock stratified syndrome systemic inflammation therapeutic therapeutic targets Treatment
[DOI] 10.1093/rheumatology/keaa652 PMC 바로가기 [Article Type] Clinical Science

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

Observational Study

Published on 2021-02-012022-10-05
Journal: The Journal of Allergy and Clinical Immunology [Category] SARS, 임상,

[키워드] 95% CI acute respiratory distress acute respiratory syndrome adjusted age alteration Anakinra Analysis anti–IL-1 association baseline bloodstream infection C-reactive protein calculated Care carried Charlson index Control Controlled trial controls coronavirus coronavirus disease Corticosteroids COVID-19 COVID-19 patient Cytokine storm death determine Efficacy and safety evaluated ferritin hazard ratio Health High-dose Hospitalization Hospitalized hyperinflammation IL-1 receptor antagonist immunomodulation Inclusion Invasive mechanical ventilation Italian Kaplan-Meier plots Laboratory mechanical ventilation median median age Methylprednisolone mitigate Mortality Observational cohort study on mechanical ventilation Oxygen therapy PaO Patient prospective observational cohort Registered Regression model Respiratory failure risk risk of death SARS-CoV-2 Severe COVID-19 pneumonia Sex significant difference significantly lower study inclusion survival syndrome therapeutic option treated treated patient
[DOI] 10.1016/j.jaci.2020.11.006 PMC 바로가기 [Article Type] Observational Study

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study

Research article

Published on 2021-02-012022-10-05
Journal: International Journal of Infectious Diseases [Category] SARS, 바이오마커,